The biotechnology company, Ncardia, develops predictive human cellular assay systems using hiPSC stem cell technology to enhance cardiovascular and neural drug screening for safety and efficacy testing of drug candidates. Their technology enables researchers and drug discovery companies to bring predictive human disease biology and accelerate drug discovery. With R&D laboratories in Leiden and production facilities in Gosselies, Ncardia is focused on the development of fully functional human assay systems, including Pluricyte Cardiomyocytes, which are highly functional cell types used in combination with phenotypic assays to deliver high-quality results.